Welcome to our dedicated page for Cyclerion Therapeutics SEC filings (Ticker: CYCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding a lab notebook. Cyclerion Therapeutics packs pages of sGC pharmacology data, trial protocols, and milestone royalty terms into every document, making it hard to spot cash-runway risks or FDA-related 8-K updates.
Stock Titan removes that barrier. Our AI engine parses each Cyclerion filing the moment it hits EDGAR, then delivers plain-English highlights—whether you’re skimming the Cyclerion Therapeutics quarterly earnings report 10-Q filing for R&D spend, or need Cyclerion insider trading Form 4 transactions in real time. Investors can instantly compare segments, track Cyclerion executive stock transactions Form 4, or dive into a Cyclerion annual report 10-K simplified summary without wading through clinical jargon.
Every document type is covered: 8-K material events explained when trial data drop, proxy statement executive compensation details for governance checks, and Form S-3 shelves that fund future studies. Use cases include:
- Flagging Cyclerion Form 4 insider transactions real-time before catalysts
- Monitoring trial-cost trends via our Cyclerion earnings report filing analysis
- Understanding Cyclerion SEC documents with AI to gauge licensing revenue potential
Cyclerion Therapeutics (CYCN) reported Q3 2025 results. Revenue was $875,000, up from $194,000 a year ago, driven mainly by $800,000 from an Akebia material purchase. The company posted a net loss of $976,000 (vs. $723,000), while year‑to‑date net loss improved to $2.7 million from $3.6 million.
Cash and cash equivalents were $4.6 million at September 30, 2025. Stockholders’ equity stood at $9.5 million. The company raised capital through a private placement (499,998 shares for approximately $1.375 million gross) and an ATM program (604,166 shares for $1.8 million net in Q3), with an additional 111,054 ATM shares sold for about $0.3 million after quarter‑end. Shares outstanding were 3,925,314 as of November 10, 2025.
Cyclerion signed a Patent License Agreement with MIT in September 2025 related to neuropsychiatric disorders, with up to $4.4 million in potential milestones and low single‑digit royalties. The olinciguat option expired without a license. Management states cash is expected to fund operations into Q2 2026, yet there is substantial doubt about the company’s ability to continue as a going concern absent additional financing.
Cyclerion Therapeutics filed an amended annual report (10-K/A) to add a missing “Critical Audit Matter” paragraph to the auditor’s report; the financial statements and notes are otherwise unchanged from the original filing.
For 2024, Cyclerion reported revenue of $2,000 thousand (license $1,750 thousand and option $250 thousand), operating expenses of $5,628 thousand, and a net loss of $3,057 thousand, narrower than 2023. Cash and cash equivalents were $3,232 thousand as of December 31, 2024. The auditor included a going concern emphasis, and management disclosed that cash is expected to fund operations through mid-2025, indicating substantial doubt about the company’s ability to continue as a going concern.
The amended audit report identifies the assessment of impairment indicators for a $5,350 thousand investment in Tisento Therapeutics Holdings Inc. as a critical audit matter; no impairment was recognized as of December 31, 2024. Under an amended Akebia license, Cyclerion received $1,250 thousand in December 2024 and is due $500 thousand in September 2025 in amendment payments, with eligibility for additional milestones. Shares outstanding were 2,710,096 as of February 28, 2025; 2,545,922 were outstanding as of December 31, 2024.
Cyclerion Therapeutics, Inc. (CYCN) reported that Chief Financial Officer Rhonda M. Chicko was granted an option to purchase 25,000 shares of common stock at an exercise price of $2.355 per share. The grant, reported with a transaction date of 08/07/2025, is under the 2019 Equity Incentive Plan. Of the 25,000 shares, 8,750 are immediately exercisable and 16,250 vest in monthly installments beginning August 31, 2025 and ending February 28, 2028, subject to continued service. The option expires August 6, 2035, and the reporting person is shown as the direct beneficial owner of the 25,000 option shares following the transaction.
FAQ
What is the current stock price of Cyclerion Therapeutics (CYCN)?
What is the market cap of Cyclerion Therapeutics (CYCN)?
